Effects of Interleukin 17 on the cardiovascular system

Autoimmunity Reviews

Volumn 16, Issue 9, 2017, Pages 984-991

  Robert, Marie ^a   Miossec, Pierre ^a  

^a University of Lyon   (France)

Author keywords

Cardiovascular disease; Chronic inflammation; Interleukin 17

Indexed keywords

CARDIOVASCULAR AGENT; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; AUTACOID;

ADVENTITIAL CELL; ANEURYSM; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL ISOLATION; CELLS BY BODY ANATOMY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; HEART INFARCTION; HEART TISSUE; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BLOOD; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-17;

EID: 85023193350     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.009     Document Type: Review

References (102)

1. Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
2. Roth, G.A., Forouzanfar, M.H., Moran, A.E., Barber, R., Nguyen, G., Feigin, V.L., et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 372 (2015), 1333–1341.
3. Ross, R., Atherosclerosis–an inflammatory disease. N Engl J Med 340 (1999), 115–126.
4. Schuett, K.A., Lehrke, M., Marx, N., Burgmaier, M., High-risk cardiovascular patients: clinical features, comorbidities, and interconnecting mechanisms. Front Immunol, 6, 2015, 591.
5. Prasad, M., Hermann, J., Gabriel, S.E., Weyand, C.M., Mulvagh, S., Mankad, R., et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 12 (2015), 168–176.
6. Roman, M.J., Shanker, B.A., Davis, A., Lockshin, M.D., Sammaritano, L., Simantov, R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 (2003), 2399–2406.
7. Tektonidou, M.G., Kravvariti, E., Konstantonis, G., Tentolouris, N., Sfikakis, P.P., Protogerou, A., Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis. Autoimmun Rev 16 (2017), 308–312.
8. Maradit-Kremers, H., Nicola, P.J., Crowson, C.S., Ballman, K.V., Gabriel, S.E., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005), 722–732.
9. Hollan, I., Meroni, P.L., Ahearn, J.M., Cohen Tervaert, J.W., Curran, S., Goodyear, C.S., et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12 (2013), 1004–1015.
10. Atzeni, F., Benucci, M., Salli, S., Bongiovanni, S., Boccassini, L., Sarzi-Puttini, P., Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 12 (2013), 575–579.
11. Miossec, P., Korn, T., Kuchroo, V.K., Interleukin-17 and type 17 helper T cells. N Engl J Med 361 (2009), 888–898.
12. Miossec, P., Kolls, J.K., Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11 (2012), 763–776.
13. Abou-Raya, A., Abou-Raya, S., Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 5 (2006), 331–337.
14. Hansson, G.K., Libby, P., The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6 (2006), 508–519.
15. von Vietinghoff, S., Ley, K., Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 21 (2010), 463–469.
16. Beringer, A., Noack, M., Miossec, P., IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med 22 (2016), 230–241.
17. Rouvier, E., Luciani, M.F., Mattei, M.G., Denizot, F., Golstein, P., CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 150 (1993), 5445–5456.
18. Aggarwal, S., Gurney, A.L., IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 71 (2002), 1–8.
19. Wright, J.F., Guo, Y., Quazi, A., Luxenberg, D.P., Bennett, F., Ross, J.F., et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4 + T cells. J Biol Chem 282 (2007), 13447–13455.
20. Aarvak, T., Chabaud, M., Miossec, P., Natvig, J.B., IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 162 (1999), 1246–1251.
21. Park, H., Li, Z., Yang, X.O., Chang, S.H., Nurieva, R., Wang, Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 (2005), 1133–1141.
22. Maddur, M.S., Miossec, P., Kaveri, S.V., Bayry, J., Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181 (2012), 8–18.
23. Noack, M., Miossec, P., Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 13 (2014), 668–677.
24. Zielinski, C.E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 484 (2012), 514–518.
25. McGeachy, M.J., Bak-Jensen, K.S., Chen, Y., Tato, C.M., Blumenschein, W., McClanahan, T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8 (2007), 1390–1397.
26. Zhou, L., Lopes, J.E., Chong, M.M., Ivanov, I.I., Min, R., Victora, G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453 (2008), 236–240.
27. Fontenot, J.D., Gavin, M.A., Rudensky, A.Y., Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol 4 (2003), 330–336.
28. Yao, Z., Fanslow, W.C., Seldin, M.F., Rousseau, A.M., Painter, S.L., Comeau, M.R., et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3 (1995), 811–821.
29. Gaffen, S.L., Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9 (2009), 556–567.
30. Iwakura, Y., Ishigame, H., Saijo, S., Nakae, S., Functional specialization of interleukin-17 family members. Immunity 34 (2011), 149–162.
31. Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 183 (1996), 2593–2603.
32. Chabaud, M., Durand, J.M., Buchs, N., Fossiez, F., Page, G., Frappart, L., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42 (1999), 963–970.
33. Hot, A., Miossec, P., Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 70 (2011), 727–732.
34. Michiels, C., Endothelial cell functions. J Cell Physiol 196 (2003), 430–443.
35. Yuan, S., Zhang, S., Zhuang, Y., Zhang, H., Bai, J., Hou, Q., Interleukin-17 stimulates STAT3-mediated endothelial cell activation for neutrophil recruitment. Cell Physiol Biochem 36 (2015), 2340–2356.
36. Erbel, C., Akhavanpoor, M., Okuyucu, D., Wangler, S., Dietz, A., Zhao, L., et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol 193 (2014), 4344–4355.
37. Hot, A., Lenief, V., Miossec, P., Combination of IL-17 and TNFalpha induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis 71 (2012), 768–776.
38. Erbel, C., Chen, L., Bea, F., Wangler, S., Celik, S., Lasitschka, F., et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol 183 (2009), 8167–8175.
39. Maione, F., Cicala, C., Liverani, E., Mascolo, N., Perretti, M., D'Acquisto, F., IL-17A increases ADP-induced platelet aggregation. Biochem Biophys Res Commun 408 (2011), 658–662.
40. Zhu, F., Wang, Q., Guo, C., Wang, X., Cao, X., Shi, Y., et al. IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin Immunol 141 (2011), 152–160.
41. Zrioual, S., Ecochard, R., Tournadre, A., Lenief, V., Cazalis, M.A., Miossec, P., Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 182 (2009), 3112–3120.
42. Lavocat, F., Maggi, L., Annunziato, F., Miossec, P., T-cell clones from Th1, Th17 or Th1/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes. Cytokine 88 (2016), 241–250.
43. Sanders, A.J., Guo, X., Mason, M.D., Jiang, W.G., IL-17B can impact on endothelial cellular traits linked to tumour angiogenesis. J Oncol, 2010, 2010, 817375.
44. Starnes, T., Broxmeyer, H.E., Robertson, M.J., Hromas, R., Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 169 (2002), 642–646.
45. Corrigan, C.J., Wang, W., Meng, Q., Fang, C., Wu, H., Reay, V., et al. T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A 108 (2011), 1579–1584.
46. Rensen, S.S., Doevendans, P.A., van Eys, G.J., Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Hear J 15 (2007), 100–108.
47. Bennett, M.R., Sinha, S., Owens, G.K., Vascular smooth muscle cells in atherosclerosis. Circ Res 118 (2016), 692–702.
48. Eid, R.E., Rao, D.A., Zhou, J., Lo, S.F., Ranjbaran, H., Gallo, A., et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 119 (2009), 1424–1432.
49. Pietrowski, E., Bender, B., Huppert, J., White, R., Luhmann, H.J., Kuhlmann, C.R., Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H- oxidase derived reactive oxygen species. J Vasc Res 48 (2011), 52–58.
50. Clarke, M.C., Littlewood, T.D., Figg, N., Maguire, J.J., Davenport, A.P., Goddard, M., et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 102 (2008), 1529–1538.
51. Gistera, A., Robertson, A.K., Andersson, J., Ketelhuth, D.F., Ovchinnikova, O., Nilsson, S.K., et al. Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med, 5, 2013, 196ra100.
52. Majesky, M.W., Dong, X.R., Hoglund, V., Mahoney, W.M. Jr., Daum, G., The adventitia: a dynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol 31 (2011), 1530–1539.
53. Shin, J.H., Shin, D.W., Noh, M., Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem Pharmacol 77 (2009), 1835–1844.
54. Zuniga, L.A., Shen, W.J., Joyce-Shaikh, B., Pyatnova, E.A., Richards, A.G., Thom, C., et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 185 (2010), 6947–6959.
55. Wu, J., Thabet, S.R., Kirabo, A., Trott, D.W., Saleh, M.A., Xiao, L., et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res 114 (2014), 616–625.
56. Woodcock, E.A., Matkovich, S.J., Cardiomyocytes structure, function and associated pathologies. Int J Biochem Cell Biol 37 (2005), 1746–1751.
57. Souders, C.A., Bowers, S.L., Baudino, T.A., Cardiac fibroblast: the renaissance cell. Circ Res 105 (2009), 1164–1176.
58. Su, S.A., Yang, D., Zhu, W., Cai, Z., Zhang, N., Zhao, L., et al. Interleukin-17A mediates cardiomyocyte apoptosis through Stat3-iNOS pathway. Biochim Biophys Acta 2016 (1863), 2784–2794.
59. Liao, Y.H., Xia, N., Zhou, S.F., Tang, T.T., Yan, X.X., Lv, B.J., et al. Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol 59 (2012), 420–429.
60. Zhou, S.F., Yuan, J., Liao, M.Y., Xia, N., Tang, T.T., Li, J.J., et al. IL-17A promotes ventricular remodeling after myocardial infarction. J Mol Med (Berl) 92 (2014), 1105–1116.
61. Cortez, D.M., Feldman, M.D., Mummidi, S., Valente, A.J., Steffensen, B., Vincenti, M., et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol 293 (2007), H3356–H3365.
62. Venkatachalam, K., Mummidi, S., Cortez, D.M., Prabhu, S.D., Valente, A.J., Chandrasekar, B., Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol 294 (2008), H2078–H2087.
63. Yan, X., Shichita, T., Katsumata, Y., Matsuhashi, T., Ito, H., Ito, K., et al. Deleterious effect of the IL-23/IL-17A axis and gammadeltaT cells on left ventricular remodeling after myocardial infarction. J Am Heart Assoc, 1, 2012, e004408.
64. Wu, L., Ong, S., Talor, M.V., Barin, J.G., Baldeviano, G.C., Kass, D.A., et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med 211 (2014), 1449–1464.
65. LaFramboise, W.A., Scalise, D., Stoodley, P., Graner, S.R., Guthrie, R.D., Magovern, J.A., et al. Cardiac fibroblasts influence cardiomyocyte phenotype in vitro. Am J Phys Cell Phys 292 (2007), C1799–C1808.
66. Gao, Q., Jiang, Y., Ma, T., Zhu, F., Gao, F., Zhang, P., et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 185 (2010), 5820–5827.
67. van Es, T., van Puijvelde, G.H., Ramos, O.H., Segers, F.M., Joosten, L.A., van den Berg, W.B., et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 388 (2009), 261–265.
68. Smith, E., Prasad, K.M., Butcher, M., Dobrian, A., Kolls, J.K., Ley, K., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121 (2010), 1746–1755.
69. Erbel, C., Dengler, T.J., Wangler, S., Lasitschka, F., Bea, F., Wambsganss, N., et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 106 (2011), 125–134.
70. Taleb, S., Romain, M., Ramkhelawon, B., Uyttenhove, C., Pasterkamp, G., Herbin, O., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 206 (2009), 2067–2077.
71. Danzaki, K., Matsui, Y., Ikesue, M., Ohta, D., Ito, K., Kanayama, M., et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 32 (2012), 273–280.
72. Tedgui, A., Mallat, Z., Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006), 515–581.
73. de Boer, O.J., Li, X., Teeling, P., Mackaay, C., Ploegmakers, H.J., van der Loos, C.M., et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 109 (2013), 290–297.
74. Simon, T., Taleb, S., Danchin, N., Laurans, L., Rousseau, B., Cattan, S., et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 34 (2013), 570–577.
75. Butcher, M.J., Waseem, T.C., Galkina, E.V., Smooth muscle cell-derived interleukin-17C plays an atherogenic role via the recruitment of proinflammatory Interleukin-17A + T cells to the aorta. Arterioscler Thromb Vasc Biol 36 (2016), 1496–1506.
76. Mantani, P.T., Duner, P., Bengtsson, E., Alm, R., Ljungcrantz, I., Soderberg, I., et al. IL-25 inhibits atherosclerosis development in apolipoprotein E deficient mice. PLoS One, 10, 2015, e0117255.
77. Sharma, A.K., Lu, G., Jester, A., Johnston, W.F., Zhao, Y., Hajzus, V.A., et al. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 126 (2012), S38–S45.
78. Ju, X., Ijaz, T., Sun, H., Ray, S., Lejeune, W., Lee, C., et al. Interleukin-6-signal transducer and activator of transcription-3 signaling mediates aortic dissections induced by angiotensin II via the T-helper lymphocyte 17-interleukin 17 axis in C57BL/6 mice. Arterioscler Thromb Vasc Biol 33 (2013), 1612–1621.
79. Wei, Z., Wang, Y., Zhang, K., Liao, Y., Ye, P., Wu, J., et al. Inhibiting the Th17/IL-17A-related inflammatory responses with digoxin confers protection against experimental abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 34 (2014), 2429–2438.
80. Chandesris, M.O., Azarine, A., Ong, K.T., Taleb, S., Boutouyrie, P., Mousseaux, E., et al. Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency. Circ Cardiovasc Genet 5 (2012), 25–34.
81. Romain, M., Taleb, S., Dalloz, M., Ponnuswamy, P., Esposito, B., Perez, N., et al. Overexpression of SOCS3 in T lymphocytes leads to impaired interleukin-17 production and severe aortic aneurysm formation in mice–brief report. Arterioscler Thromb Vasc Biol 33 (2013), 581–584.
82. Barry, S.P., Ounzain, S., McCormick, J., Scarabelli, T.M., Chen-Scarabelli, C., Saravolatz, L.I., et al. Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol 163 (2013), 326–334.
83. Hashmi, S., Zeng, Q.T., Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 17 (2006), 699–706.
84. Cheng, X., Yu, X., Ding, Y.J., Fu, Q.Q., Xie, J.J., Tang, T.T., et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 127 (2008), 89–97.
85. Shichita, T., Sugiyama, Y., Ooboshi, H., Sugimori, H., Nakagawa, R., Takada, I., et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15 (2009), 946–950.
86. Gelderblom, M., Weymar, A., Bernreuther, C., Velden, J., Arunachalam, P., Steinbach, K., et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood 120 (2012), 3793–3802.
87. Li, G.Z., Zhong, D., Yang, L.M., Sun, B., Zhong, Z.H., Yin, Y.H., et al. Expression of interleukin-17 in ischemic brain tissue. Scand J Immunol 62 (2005), 481–486.
88. Nguyen, H., Chiasson, V.L., Chatterjee, P., Kopriva, S.E., Young, K.J., Mitchell, B.M., Interleukin-17 causes rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res 97 (2013), 696–704.
89. Madhur, M.S., Lob, H.E., McCann, L.A., Iwakura, Y., Blinder, Y., Guzik, T.J., et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55 (2010), 500–507.
90. Karbach, S., Croxford, A.L., Oelze, M., Schuler, R., Minwegen, D., Wegner, J., et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease. Arterioscler Thromb Vasc Biol 34 (2014), 2658–2668.
91. Kwak, B., Mulhaupt, F., Myit, S., Mach, F., Statins as a newly recognized type of immunomodulator. Nat Med 6 (2000), 1399–1402.
92. Kwak, B.R., Mulhaupt, F., Mach, F., Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2 (2003), 332–338.
93. Imamura, M., Okunishi, K., Ohtsu, H., Nakagome, K., Harada, H., Tanaka, R., et al. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax 64 (2009), 44–49.
94. Zhang, X., Jin, J., Peng, X., Ramgolam, V.S., Markovic-Plese, S., Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4 + lymphocytes. J Immunol 180 (2008), 6988–6996.
95. Hot, A., Lavocat, F., Lenief, V., Miossec, P., Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Ann Rheum Dis 72 (2013), 754–760.
96. DeForge, L.E., Loyet, K.M., Delarosa, D., Chinn, J., Zamanian, F., Chuntharapai, A., et al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J Immunol Methods 362 (2010), 70–81.
97. Ndongo-Thiam, N., Clement, A., Pin, J.J., Razanajaona-Doll, D., Miossec, P., Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis. Ann Rheum Dis 75 (2016), 1420–1422.
98. Singh, R., Aggarwal, A., Misra, R., Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 34 (2007), 2285–2290.
99. Ndongo-Thiam, N., Miossec, P., A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis. Ann Rheum Dis 74 (2015), 1629–1631.
100. Griffiths, C.E., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386 (2015), 541–551.
101. Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., et al. Phase 3 studies comparing Brodalumab with Ustekinumab in psoriasis. N Engl J Med 373 (2015), 1318–1328.
102. Van Tassell, B.W., Toldo, S., Mezzaroma, E., Abbate, A., Targeting interleukin-1 in heart disease. Circulation 128 (2013), 1910–1923.